Clinical TrialApr 27, 2026, 04:47 PM
ACRS to Announce ATI-052 Phase 1a Results & ATI-2138 Indication
AI Summary
Aclaris Therapeutics, Inc. announced it will release full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 on April 28, 2026, before market open. The company will host a webcast and conference call at 8:30 AM EST on the same day to discuss these updates. Aclaris is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases.
Key Highlights
- Full Phase 1a results for ATI-052 to be announced April 28, 2026.
- Lead indication selection results for ATI-2138 to be announced April 28, 2026.
- Webcast and conference call scheduled for April 28, 2026, at 8:30 AM EST.
- ATI-052 is an anti-TSLP/IL-4R bispecific antibody.
- ATI-2138 is an ITK/JAK3 Inhibitor.
Price Impact
More from ACRS